U.S. markets closed
  • S&P 500

    3,818.83
    -2.72 (-0.07%)
     
  • Dow 30

    31,029.31
    +82.32 (+0.27%)
     
  • Nasdaq

    11,177.89
    -3.65 (-0.03%)
     
  • Russell 2000

    1,719.37
    -19.47 (-1.12%)
     
  • Crude Oil

    109.57
    -0.21 (-0.19%)
     
  • Gold

    1,819.10
    +1.60 (+0.09%)
     
  • Silver

    20.73
    -0.01 (-0.04%)
     
  • EUR/USD

    1.0448
    -0.0077 (-0.73%)
     
  • 10-Yr Bond

    3.0930
    -0.1130 (-3.52%)
     
  • GBP/USD

    1.2125
    -0.0059 (-0.49%)
     
  • USD/JPY

    136.5590
    +0.4310 (+0.32%)
     
  • BTC-USD

    20,169.03
    -140.07 (-0.69%)
     
  • CMC Crypto 200

    434.46
    -5.20 (-1.18%)
     
  • FTSE 100

    7,312.32
    -11.09 (-0.15%)
     
  • Nikkei 225

    26,804.60
    -244.87 (-0.91%)
     

RxSight Announces Updated Date for Reporting Second Quarter 2021 Financial Results on September 9, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

ALISO VIEJO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., (NASDAQ: RXST) an ophthalmic medical device company, today announced an updated date for reporting second quarter 2021 financial results. In observance of the Rosh Hashanah holiday, the company will now report after the market close on Thursday, September 9, 2021. Management will discuss the results during a conference call beginning that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at https://investors.rxsight.com/.

About RxSight, Inc.
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The LAL now features ActivShield™ technology, a revolutionary UV protection layer built into the lens. Additional information about RxSight can be found at www.rxsight.com.

Investor Relations Contact:
Philip Taylor
Gilmartin Group
415.937.5406
IR@rxsight.com

Company contact:
Roy Freeman
Sr. Director, Marketing
rfreeman@rxsight.com